• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血脂异常的诊断与治疗:儿童和青少年的风险分层

Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents.

作者信息

Mosca Sara, Araújo Graça, Costa Vanessa, Correia Joana, Bandeira Anabela, Martins Esmeralda, Mansilha Helena, Tavares Mónica, Coelho Margarida P

机构信息

Pediatrics Department, Centro Materno-Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto 4050-651, Portugal.

Pediatrics Department, Hospital Central do Funchal, Funchal 9000-177, Portugal.

出版信息

J Nutr Metab. 2022 Feb 21;2022:4782344. doi: 10.1155/2022/4782344. eCollection 2022.

DOI:10.1155/2022/4782344
PMID:35237450
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8885266/
Abstract

Dyslipidemias or dyslipoproteinemias are quantitative changes in total cholesterol concentration, respective fractions, or triglycerides in the plasma. Evidence supported that dyslipidemia in childhood is associated with atherosclerosis in adulthood, and early identification and treatment potentially reduce cardiovascular risk in adulthood, which is the principal cause of morbidity and mortality in developed countries. Dyslipidemias can result from primary lipoprotein metabolism changes due to different genetic causes (primary dyslipidemias) or as a consequence of exogenous factors or other pathologies (secondary dyslipidemias). Therefore, the combined dyslipidemias result from the association of important epigenetic and environmental influences with risk factors for cardiovascular disease. The criterion for lipid metabolism screening at young ages is not widely accepted and possibly follows a universal or directed screening strategy. Additionally, little is known about its long-term effects or possible risk-benefit despite the growing tendency to start pharmacological therapy. Therefore, this study aimed to review the available bibliography on dyslipidemia in pediatric age to present a practical and structured approach to dyslipidemia that focuses on screening, risk stratification for atherosclerotic disease, and therapeutic approach.

摘要

血脂异常或脂蛋白异常血症是指血浆中总胆固醇浓度、各组分或甘油三酯的定量变化。有证据表明,儿童期血脂异常与成年期动脉粥样硬化有关,早期识别和治疗可能降低成年期心血管疾病风险,而心血管疾病是发达国家发病和死亡的主要原因。血脂异常可能源于不同遗传原因导致的原发性脂蛋白代谢变化(原发性血脂异常),或外源性因素或其他病理状况的结果(继发性血脂异常)。因此,合并性血脂异常是重要的表观遗传和环境影响与心血管疾病危险因素共同作用的结果。在年轻人群中进行脂质代谢筛查的标准尚未得到广泛认可,可能遵循通用或针对性的筛查策略。此外,尽管开始药物治疗的趋势日益增加,但对其长期影响或可能的风险效益知之甚少。因此,本研究旨在回顾有关儿童期血脂异常的现有文献,以提出一种实用且结构化的血脂异常处理方法,重点关注筛查、动脉粥样硬化疾病风险分层和治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8ca/8885266/8c6d3b30a2f7/jnme2022-4782344.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8ca/8885266/08f45105221a/jnme2022-4782344.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8ca/8885266/43af980ba042/jnme2022-4782344.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8ca/8885266/8c6d3b30a2f7/jnme2022-4782344.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8ca/8885266/08f45105221a/jnme2022-4782344.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8ca/8885266/43af980ba042/jnme2022-4782344.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8ca/8885266/8c6d3b30a2f7/jnme2022-4782344.003.jpg

相似文献

1
Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents.血脂异常的诊断与治疗:儿童和青少年的风险分层
J Nutr Metab. 2022 Feb 21;2022:4782344. doi: 10.1155/2022/4782344. eCollection 2022.
2
3
4
5
The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study.儿童低密度和高密度脂蛋白胆固醇血脂异常分类以及血脂异常状态变化与成年期颈动脉内膜中层厚度的关联:来自芬兰青年人心血管风险研究、博加卢萨心脏研究和成人健康儿童决定因素(CDAH)研究的证据
J Am Coll Cardiol. 2009 Mar 10;53(10):860-9. doi: 10.1016/j.jacc.2008.09.061.
6
Lipid Screening in Childhood and Adolescence for Detection of Multifactorial Dyslipidemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.儿童和青少年血脂筛查:多因素血脂异常检测的证据报告和美国预防服务工作组系统评价。
JAMA. 2016 Aug 9;316(6):634-44. doi: 10.1001/jama.2016.6423.
7
Dyslipidemia in pediatrician's practice.儿科医生实践中的血脂异常。
Rev Cardiovasc Med. 2021 Sep 24;22(3):817-834. doi: 10.31083/j.rcm2203088.
8
Screening and Management of Dyslipidemia in Children and Adolescents.儿童和青少年血脂异常的筛查与管理
J Clin Med. 2022 Oct 31;11(21):6479. doi: 10.3390/jcm11216479.
9
Adult dyslipidemia prediction is improved by repeated measurements in childhood and young adulthood. The Cardiovascular Risk in Young Finns Study.通过在儿童期和青年期重复测量可改善成人血脂异常的预测。芬兰青年人心血管风险研究。
Atherosclerosis. 2015 Apr;239(2):350-7. doi: 10.1016/j.atherosclerosis.2015.02.004. Epub 2015 Feb 7.
10
Universal screening of cholesterol in children.儿童胆固醇的普遍筛查。
Clin Cardiol. 2012 Nov;35(11):662-4. doi: 10.1002/clc.22050. Epub 2012 Aug 28.

引用本文的文献

1
Effects of vitamin E administration on serum lipid profile in diabetic patients: a grade-assessed systematic review and dose-response meta-analysis of RCTs.维生素E给药对糖尿病患者血脂谱的影响:一项基于随机对照试验的分级评估系统评价和剂量反应荟萃分析。
Diabetol Metab Syndr. 2025 Jul 18;17(1):280. doi: 10.1186/s13098-025-01833-2.
2
The Impact of Dyslipidemia on the Clinical Profile of Patients With Uncontrolled Diabetes.血脂异常对未控制糖尿病患者临床特征的影响。
In Vivo. 2025 Jul-Aug;39(4):2243-2258. doi: 10.21873/invivo.14020.
3
Cardiovascular Risk Factors Among Young People in Haiti: Implications for Low-Income Countries.

本文引用的文献

1
Obesity and Cardiometabolic Risk Factors: From Childhood to Adulthood.肥胖与心脏代谢危险因素:从儿童到成年。
Nutrients. 2021 Nov 22;13(11):4176. doi: 10.3390/nu13114176.
2
Treatment of Dyslipidaemia in Children.儿童血脂异常的治疗
Biomedicines. 2021 Aug 24;9(9):1078. doi: 10.3390/biomedicines9091078.
3
Hyperlipidemia.高脂血症
海地年轻人中的心血管危险因素:对低收入国家的启示
Glob Heart. 2025 Jun 10;20(1):52. doi: 10.5334/gh.1435. eCollection 2025.
4
The risk factors for cardiovascular disease and chronic kidney disease in patients with nonalcoholic fatty liver disease in Saudi Arabia.沙特阿拉伯非酒精性脂肪性肝病患者心血管疾病和慢性肾脏病的危险因素。
Saudi Med J. 2025 May;46(5):478-490. doi: 10.15537/smj.2025.46.5.20240901.
5
Post-marketing quality assessment of some brands of rosuvastatin tablets available in Jos, North-Central Nigeria.尼日利亚中北部乔斯市市场上部分品牌瑞舒伐他汀片的上市后质量评估。
BMC Chem. 2025 Apr 26;19(1):112. doi: 10.1186/s13065-025-01470-w.
6
[Inappropriate eating habits are associated with hypercholesterolemia in adolescents].[不良饮食习惯与青少年高胆固醇血症有关]
Rev Med Inst Mex Seguro Soc. 2024 Jul 1;62(4):1-8. doi: 10.5281/zenodo.11397150.
7
Evaluating Dyslipidemia and Atherogenic Indices as Predictors of Coronary Artery Disease Risk: A Retrospective Cross-Sectional Study.评估血脂异常和致动脉粥样硬化指数作为冠状动脉疾病风险预测指标:一项回顾性横断面研究。
Cureus. 2024 Oct 10;16(10):e71187. doi: 10.7759/cureus.71187. eCollection 2024 Oct.
8
Dietary bamboo charcoal powder ameliorates high-fat diet-induced hyperlipidemia by enhancing fecal lipid excretions in Sprague-Dawley rats.膳食竹炭粉通过增强斯普拉格-道利大鼠粪便脂质排泄来改善高脂饮食诱导的高脂血症。
Front Nutr. 2024 Oct 9;11:1458350. doi: 10.3389/fnut.2024.1458350. eCollection 2024.
9
Childhood Cardiovascular Health, Obesity, and Some Related Disorders: Insights into Chronic Inflammation and Oxidative Stress.儿童心血管健康、肥胖症及相关疾病:慢性炎症与氧化应激的启示。
Int J Mol Sci. 2024 Sep 7;25(17):9706. doi: 10.3390/ijms25179706.
10
Molecular Aspects in the Development of Type 2 Diabetes and Possible Preventive and Complementary Therapies.2 型糖尿病发病机制中的分子方面及可能的预防和补充治疗。
Int J Mol Sci. 2024 Aug 22;25(16):9113. doi: 10.3390/ijms25169113.
Pediatr Rev. 2020 Aug;41(8):393-402. doi: 10.1542/pir.2019-0053.
4
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes.脂蛋白(a)浓度与心血管疾病和糖尿病风险。
J Am Coll Cardiol. 2019 Dec 17;74(24):2982-2994. doi: 10.1016/j.jacc.2019.10.019. Epub 2019 Dec 9.
5
Clinical Practice Recommendations for Pediatric Dyslipidemia.儿科血脂异常临床实践建议。
J Pediatr Health Care. 2019 Jul-Aug;33(4):494-504. doi: 10.1016/j.pedhc.2019.02.009.
6
Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association.高危儿科患者的心血管风险降低:美国心脏协会的科学声明。
Circulation. 2019 Mar 26;139(13):e603-e634. doi: 10.1161/CIR.0000000000000618.
7
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2018 年美国心脏病学会/美国心脏协会/美国心血管血管造影和介入学会/美国预防、物理治疗和康复医师学会/美国糖尿病协会/美国老年学会/美国药学会/美国医师协会/美国生理学会/北美介入放射学会/美国国家脂质协会/美国临床内分泌医师协会胆固醇管理指南:美国心脏病学会/美国心脏协会临床实践指南工作组的报告。
Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10.
8
Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.家族性高胆固醇血症的临床基因检测:美国心脏病学会科学专家组。
J Am Coll Cardiol. 2018 Aug 7;72(6):662-680. doi: 10.1016/j.jacc.2018.05.044.
9
The complex molecular genetics of familial hypercholesterolaemia.家族性高胆固醇血症的复杂分子遗传学。
Nat Rev Cardiol. 2019 Jan;16(1):9-20. doi: 10.1038/s41569-018-0052-6.
10
Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.儿童和青少年血脂异常筛查:美国预防服务工作组推荐声明。
JAMA. 2016 Aug 9;316(6):625-33. doi: 10.1001/jama.2016.9852.